Skip to content

Kivexa downgraded to alternative status in revised US HIV treatment guidelines

Raltegravir resistance patterns becoming clearer

Resistance to darunavir related to pre-existing mutations

Higher levels of drug resistance seen after first-line NNRTI failure than boosted PI failure: meta-analysis

Cluster of multi-drug resistant HIV transmissions in Seattle

Widespread NRTI and NNRTI resistance seen in Malawian patients failing first-line antiretroviral therapy

Low level of drug-resistant strains common in untreated patients, but may not affect treatment

Untreated HIV infection may facilitate rifampicin-resistant and multi-drug-resistant TB strains

Boosted protease inhibitors have 60% lower risk of resistance compared with other classes